第三阶段非精子瘤丸癌患者的条件生存率
Reha-Baris Incesu1, Francesco Barletta2, Stefano Tappero3
1Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Urologic oncology
|August 9, 2023
概括
条件生存改善了第三阶段非精子瘤丸癌患者的预后预测. 36个月的无病间隔显著提高了生存前景,比单独的初始诊断提供了更乐观的观点.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 临床流行病学 临床流行病学
背景情况:
- 癌症存活风险通常会随着治疗后长时间的无病间隔而降低.
- 条件生存率,即从未来的某一点生存到现在的生存概率,在第三阶段非精子瘤中没有得到充分的研究.
- 准确的生存预后对于晚期癌症的临床决策至关重要.
研究的目的:
- 调查无病间隔持续时间对第三阶段非精子瘤丸癌患者的整体存活率的影响.
- 评估条件生存估计在改进该患者群体的预后中的有用性.
主要方法:
- 利用监测,流行病学和最终结果数据库 (2004-2018) 来识别患有第三阶段非精子瘤的患者.
- 应用多变量考克斯回归分析来评估死亡率预测因素.
- 采用条件生存模型,专注于36个月的无病间隔,以估计长期生存率.
主要成果:
- 在2,092名患者中,预后组被定义为:好 (18%),中等 (27%),差 (55%).
- 预后不佳独立预测了较高的整体死亡率 (HR 3.3,P < 0.001).
- 与初始预测相比,36个月的有条件生存显著改善了5年生存估计,特别是在预后不佳组 (+29%).
结论:
- 条件生存估计,特别是经过36个月的无病间隔后,为第三阶段非血瘤患者提供了更准确和更乐观的前景.
- 这些更新的预后提供了超出初始诊断预测的宝贵见解,有助于临床管理和患者咨询.
相关概念视频
01:21Cancer Survival Analysis
384
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
384
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K